EGFR and non-small cell lung carcinoma: For advanced EGFR-mutated NSCLC, it is crucial to investigate novel EGFR-TKIs or therapeutic compounds demonstrating biological synergy with EGFR-TKIs, as acquired resistance to these inhibitors invariably develops, and NSCLC patients eventually experience disease progression [53].